Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ropinirole extended-release - GlaxoSmithKline

Next Previous
X
Search
Drug Profile

Ropinirole extended-release - GlaxoSmithKline

Alternative Names: Requip CR; Requip LP; Requip Modutab/XL 24-hour; Requip XL; Requip XR; RequipP XL 24-hour Extended-Release Tablets; Ropinirole controlled-release; Ropinirole CR; Ropinirole ER; Ropinirole LP; Ropinirole PR; Ropinirole prolonged-release; Ropinirole XL; Ropinirole XR; SKF 101468A

Latest Information Update: 05 Nov 2023

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator GlaxoSmithKline
  • Developer GlaxoSmithKline; GSK; K Pharma
  • Class Amines; Antiparkinsonians; Indoles; Sleep disorder therapies; Small molecules
  • Mechanism of Action Dopamine D2 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Parkinson's disease; Restless legs syndrome
  • Phase I/II Amyotrophic lateral sclerosis

Most Recent Events

  • 27 Aug 2019 No development reported - Phase-III for Parkinson's disease (Monotherapy) in Japan (PO)
  • 17 Oct 2017 GlaxoSmithKline terminates a phase III trial in Parkinson's disease in Japan (PO) (NCT01929317)
  • 01 Jun 2015 GlaxoSmithKline completes a phase III trial in Parkinson's disease in Japan (PO) (NCT01929317)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top